Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.
2 reports, 1 independent
Updated Aug 24
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alvotech
biotechnology company
-
Bank of America
American multinational banking and financial services corporation